As Sanofi and Regeneron scramble to keep their cholesterol drug Praluent on the market amid a contentious patent fight, Amgen’s rival drug Repatha already…

Allergan CEO Brent Saunders is tired of hearing from investors that chin-fat buster Kybella’s launch isn’t going as well as those of his company's other…

Merck & Co. is another step closer to eclipsing its I-O competitors thanks to an unexpectedly quick filing for a new Keytruda-chemo combo.

Takeda plans to shell out $5.2 billion for the kind of deal most major drugmakers want: Ariad, its leukemia drug Iclusig and a pipeline with near-term…

At Eli Lilly, the new year comes with a shakeup in its commercial organization, with vet Enrique Conterno taking the reins in the U.S. and ex-Novartis exec…

Biogen's $375,000-plus price on its new drug Spinraza set analysts and market watchers atwitter. Will the ultra-orphan med become the "Sovaldi of…

Last month, Pfizer hit the market with Inflectra. And with the launch came not only the beginning of a new class of copycats, but a new way to go to market.

When Eli Lilly set aside its Alzheimer’s prospect solanezumab, it also put a set of sales jobs on the chopping block.

Can Roche's Gazyva edge Rituxan even with biosims looming? At least one analyst thinks it may be the only second-gen blood cancer med with a chance to…

Launches